The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
The authors describe the epidemiology of invasive Hib and nontype b H. influenzae infections in children <15 years of age in the United Kingdom from 1994 until 2008, and show that the resurgence in Hib disease during the years 1999-2003 did not affect the epidemiology of invasive nontype b H. influenzae disease in children, which provides further support against serotype replacement.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T